Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Multidisciplinary model to implement pharmacogenomics at the point of care.

Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM.

Genet Med. 2017 Apr;19(4):421-429. doi: 10.1038/gim.2016.120. Epub 2016 Sep 22.

2.

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.

Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR.

Blood Cancer J. 2015 Aug 28;5:e346. doi: 10.1038/bcj.2015.69.

3.

TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ, Ansell SM.

Leukemia. 2014 Sep;28(9):1872-84. doi: 10.1038/leu.2014.84. Epub 2014 Feb 26.

4.

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.

Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T, Ziesmer S, Li Y, Johnson SH, Hart SN, Kocher JP, Vasmatzis G, Chanan-Kahn A, Gertz M, Fonseca R, Dogan A, Cerhan JR, Novak AJ.

Blood Cancer J. 2014 Feb 14;4:e183. doi: 10.1038/bcj.2014.4.

5.

Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.

Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Novak AJ, Ansell SM.

Blood. 2014 Feb 13;123(7):1055-8. doi: 10.1182/blood-2013-08-521963. Epub 2013 Dec 11.

6.

B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.

Secreto F, Manske M, Price-Troska T, Ziesmer S, Hodge LS, Ansell SM, Cerhan JR, Novak AJ.

Leuk Lymphoma. 2014 Aug;55(8):1884-92. doi: 10.3109/10428194.2013.862619. Epub 2014 Feb 24.

7.

Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma.

Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM.

Clin Cancer Res. 2013 Dec 15;19(24):6812-9. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18.

8.

Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.

Hodge LS, Ansell SM.

Transfus Apher Sci. 2013 Aug;49(1):19-23. doi: 10.1016/j.transci.2013.05.019. Epub 2013 Jun 15.

PMID:
23773867
9.

Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma.

Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Yates NR, Secreto FJ, Hodge LS, Witzig TE, Novak AJ, Ansell SM.

PLoS One. 2013;8(3):e59456. doi: 10.1371/journal.pone.0059456. Epub 2013 Mar 15.

10.

IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.

Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA, Novak AJ, Ansell SM.

Blood. 2012 Nov 1;120(18):3774-82. doi: 10.1182/blood-2012-03-419440. Epub 2012 Sep 13.

PMID:
22976953
11.

MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts.

Hodge LS, Elsawa SF, Grote DM, Price-Troska TL, Asmann YW, Fonseca R, Gertz MA, Witzig TE, Novak AJ, Ansell SM.

Blood Cancer J. 2011 Jun;1(6):e24. doi: 10.1038/bcj.2011.25. Epub 2011 Jun 17.

12.

Localized delivery of chemotherapy to the cervix for radiosensitization.

Hodge LS, Downs LS Jr, Chura JC, Thomas SG, Callery PS, Soisson AP, Kramer P, Wolfe SS, Tracy TS.

Gynecol Oncol. 2012 Oct;127(1):121-5. doi: 10.1016/j.ygyno.2012.07.097. Epub 2012 Jul 14.

PMID:
22796462
13.

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, Witzig TE, Fernandez-Zapico ME, Ansell SM.

Blood. 2011 Nov 17;118(20):5540-9. doi: 10.1182/blood-2011-04-351742. Epub 2011 Sep 14.

14.

The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.

Hodge LS, Taub ME, Tracy TS.

Drug Metab Dispos. 2011 Nov;39(11):2013-6. doi: 10.1124/dmd.111.040790. Epub 2011 Aug 10.

PMID:
21832002
15.

Jak/Stat pathway in Waldenström's macroglobulinemia.

Hodge LS, Ansell SM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):112-4. doi: 10.3816/CLML.2011.n.023.

PMID:
21454207
16.

Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.

Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, Price Troska TL, Ziesmer SC, Fonseca R, Witzig TE, Morice WG, Gertz MA, Ansell SM.

Blood. 2011 May 12;117(19):e190-7. doi: 10.1182/blood-2010-12-326868. Epub 2011 Mar 17.

PMID:
21415268
17.

Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.

Hodge LS, Taub ME, Tracy TS.

Biochem Pharmacol. 2011 Apr 1;81(7):950-6. doi: 10.1016/j.bcp.2011.01.016. Epub 2011 Feb 1.

PMID:
21291869
18.

Alterations in drug disposition during pregnancy: implications for drug therapy.

Hodge LS, Tracy TS.

Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):557-71. Review.

PMID:
17696806

Supplemental Content

Loading ...
Support Center